Globus Medical (GMED) Q1 2026 earnings review
Massive Profitability Surge Masks Underlying Top-Line Slowdown
Globus Medical delivered a highly profitable Q1 2026, proving it can successfully digest massive M&A targets. Total revenue surged 27% to $759.9M, largely flattered by the Nevro acquisition, but organic growth remained robust at 13.2%. The real story is the bottom line: operating leverage and disciplined NuVasive synergy capture drove a massive 65% jump in non-GAAP EPS to $1.12. However, while management confidently raised full-year EPS guidance to $4.70-$4.80, they curiously maintained their $3.18B-$3.22B revenue target. Given the Q1 beat, this implies a sharp deceleration for the remainder of the year as the Nevro acquisition anniversaries.
🐂 Bull Case
Adjusted EBITDA margin hit 32.3%, up 260 bps YoY. Globus is successfully wringing out redundancies from the NuVasive and Nevro deals, proving management's reputation for extreme operational discipline.
US Spine continues to take market share, posting its third consecutive quarter of 10%+ organic growth. Competitive rep recruiting and deep product portfolios are translating directly to the top line.
🐻 Bear Case
Reaffirming the $3.2B revenue guide after a $760M Q1 implies only ~4% YoY growth for the remaining three quarters of 2026. The easy YoY Nevro comps end in Q2.
Enabling Technologies plummeted sequentially to $26.9M from $55.6M in 25Q4. Hospital capital constraints and a shift to leasing models continue to create extreme revenue lumpiness.
⚖️ Verdict: 🟢
Bullish. The sheer magnitude of the EPS beat (+65%) and the structural margin improvements outshine the concerns over lumpy capital sales and implied top-line deceleration.
Key Themes
Base Business Growth Accelerating
Stripping away the noise of the Nevro acquisition, Globus's underlying operations are accelerating. Base business revenue grew 13.2% YoY, continuing a flawless upward trajectory from -1.4% in 25Q1, to +3.3% in 25Q2, to +7.0% in 25Q3, to +10.0% in 25Q4. US Spine is leading the charge, driven by strong procedural volumes and successful market share capture.
Relentless M&A Synergy Execution
Globus has systematically dismantled the narrative that the NuVasive and Nevro acquisitions would bloat the company. Through disciplined manufacturing integration and structural cost actions, operating income soared to $150.4M from $97.0M a year ago. Management has essentially proven they can acquire lower-margin competitors and rapidly enforce the high-margin 'Globus mindset'.
Excelsius Ecosystem Moat
The closed-loop surgical intelligence system (patient selection, navigation, robotics, implants) remains the primary long-term growth driver. Despite near-term capital sales volatility, the overarching strategy of placing systems to guarantee long-term, high-margin implant pull-through remains intact.
The Hidden Deceleration in Guidance
A severe disconnect exists between Q1's narrative and the full-year outlook. Despite Q1 generating $760M in revenue (+27% YoY), management merely reaffirmed the $3.18B-$3.22B full-year target. At the midpoint ($3.20B), this leaves $2.44B for the next three quarters. In 2025, Q2-Q4 delivered $2.34B. This implies total revenue growth will collapse to roughly 4.2% YoY for the remainder of the year. This either highlights extreme management conservatism or signals a sharp slowdown as the Nevro acquisition laps its one-year anniversary in Q2.
Enabling Technologies Revenue Whiplash
Enabling Technologies (robotics/navigation) remains highly erratic. After a record $55.6M in 25Q4, revenue collapsed sequentially by over 50% to $26.9M in 26Q1. While up slightly YoY (+21%), this highlights ongoing hospital capital spending constraints and the negative near-term accounting impact of shifting to operating leases instead of upfront cash sales.
Macro Impact: Hospital Capital Constraints
As noted in prior quarters, the macro environment for large hospital capital purchases remains strained. Increased competition and internal hospital ROI reviews are elongating deal cycles. Globus's pivot toward flexible capital deal structures (leases, pay-per-click) mitigates lost deals but directly dampens immediate revenue recognition.
Other KPIs
Accelerating. Up 15% from a strong $141.2M in the prior year period. Globus continues to convert net income into cash exceptionally well. This rapid cash generation pushed Total Cash & Marketable Securities to nearly $800M, reloading the powder keg for further M&A or share repurchases.
Decelerating sequentially. Nevro contributed $94.6M in 25Q2, $99.3M in 25Q3, and $99.7M in 25Q4. The $82.7M print in 26Q1 represents a notable sequential step-down, suggesting that while cost-cutting synergies are working, stabilizing the acquired top line in the neuromodulation market remains a work in progress.
Guidance
Accelerating. Increased from the previous range of $4.40 - $4.50. At the midpoint ($4.75), this implies a massive 19.3% YoY growth compared to the $3.98 delivered in FY25. This underscores management's high confidence in continued margin expansion and cost control.
Stable/Reaffirmed. Implies 8.3% to 9.7% annual growth. Because the company generated 27% growth in Q1, achieving this full-year guidance requires growth to decelerate sharply into the mid-single digits for the rest of the year, likely due to lapping the Nevro acquisition.
Key Questions
Revenue Guidance Conservatism
With 13.2% organic growth in Q1, why was full-year revenue guidance merely reaffirmed? Does this reflect caution around the capital equipment environment, or expected disruption as Nevro anniversaries?
Nevro Sequential Decline
Nevro revenue stepped down sequentially to $82.7M in Q1 from roughly $100M in previous quarters. How much of this is typical Q1 seasonality versus disruption from sales force integration and aggressive cost-cutting?
Capital Allocation Strategy
With nearly $800M in cash and marketable securities and $160M+ in quarterly free cash flow, what is the priority for capital deployment now that the debt is gone? Should investors expect an acceleration in the buyback program?